Drugs / Dositinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07362940 | Nov 2025 → Jul 2027 expected | non-small cell lung carcinoma | Henan Genuine Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07231068 | Oct 2022 → Dec 2027 expected | non-small cell lung carcinoma | Henan Genuine Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dositinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231068 ↗ |
| Action | Inhibit | “Dositinib is an EGFR-TKI.” NCT07231068 ↗ |
| Modality | Small molecule | “Dositinib is an EGFR-TKI.” NCT07231068 ↗ |
| Route | Oral | “once-daily oral administration of GEN-725 tablets in combination with Dositinib mesylate tablets” NCT07362940 ↗ |
| Target | EGFR | “Dositinib is an EGFR-TKI.” NCT07231068 ↗ |